Clik here to view.
CARsgen Releases the First Clinical Batch of CAR T Cells from its RTP GMP...
SHANGHAI CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces...
View ArticleClik here to view.
Orum Therapeutics to Participate at Investor Conferences in September
BOSTON & DAEJEON, South Korea Orum Therapeutics, a private clinical stage biotechnology company pioneering the development of tumor-directed targeted protein degraders (TPDs), today announced...
View ArticleClik here to view.
Cellusion and Celregen, a member of Fosun Pharma, Enter into Exclusive...
TOKYO & HANGZHOU, China & SHANGHAI Cellusion Inc. (CEO: Shin Hatou, M.D. Ph.D., “Cellusion”), a Japanese regenerative medicine startup aiming to solve the global corneal transplant waiting...
View ArticleClik here to view.
PDC*line Pharma Presents First Clinical Results From Phase I/II trial With...
LIÈGE, Belgium & GRENOBLE, France PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, today announces the first...
View ArticleClik here to view.
Takeda Receives Positive CHMP Opinion for Maribavir for the Treatment of...
OSAKA, Japan & CAMBRIDGE, Mass. Takeda (TSE:4502/NYSE:TAK) today announced the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the...
View ArticleClik here to view.
Prolific Machinesがトップクラスのプラネタリーヘルス投資家から4200万ドルを調達し、生物学組立ラインを構築へ
サンフランシスコ （ビジネスワイヤ） — 次世代バイオテクノロジー企業のProlific...
View ArticleClik here to view.
Prolific Machines从顶级的星球健康投资人筹集了4,200万美元，用于建立生物学生产线
旧金山 (美国商业资讯)–新一代生物技术公司Prolific Machines今天走出隐身模式，宣布其种子轮和A轮融资实现大幅超额认购。两轮融资均由该领域一流的风险投资人领投。种子轮融资由人造肉的首位投资人、梅菲尔德风险投资公司(Mayfield)的Arvind Gupta领投。A轮融资由比尔·盖茨创立的Breakthrough Energy...
View ArticleClik here to view.
Global Cord Blood Corporation Announces Appointment of Joint Provisional...
HONG KONG Global Cord Blood Corporation (NYSE: CO) (“GCBC” or the “Company”), China’s leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell...
View ArticleClik here to view.
Autologous immune-cell therapy, practiced in Japan, now helping Vinmec...
TOKYO Treatment of cancer using one’s own immune cells, natural killer (NK) cells and T-cells, called autologous immune enhancement cell therapy (AIET) administered along with conventional...
View ArticleClik here to view.
Clik here to view.
在日本实施的自体免疫细胞疗法在GN Corporation技术转让后帮助Vinmec医院治疗越南河内的癌症患者
东京 (美国商业资讯)–自体免疫增强细胞疗法(AIET)利用个人自身的免疫细胞、自然杀伤细胞(NK)和T细胞治疗癌症。该疗法与传统的化疗、放疗和手术联用，已在日本长时间实施。在GN...
View ArticleClik here to view.
Cellusion and Minaris Regenerative Medicine, a member of Showa Denko...
TOKYO Cellusion Inc. (CEO: Shin Hatou, M.D. Ph.D., “Cellusion”), a Japanese regenerative medicine startup aiming to solve the global corneal transplant waiting list problem with a unique...
View ArticleClik here to view.
Veristat Joins Decentralized Trials ＆ Research Alliance (DTRA) to Improve the...
SOUTHBOROUGH, Mass. Veristat announced that it has joined an alliance of over 120 life sciences and healthcare organizations whose mission is to accelerate the broad adoption of patient-focused,...
View ArticleClik here to view.
Qihan Biotech Appoints Tony W. Ho to its Board of Directors
HANGZHOU, China Hangzhou Qihan Biotech Co., Ltd. (“Qihan” or “Qihan Biotech” or “the Company”), an industry leader in applying multiplexable genome editing technology to cell therapies and organ...
View ArticleClik here to view.
Immunis Chairman Dr. Hans Keirstead Visits His Holiness the Dalai Lama
IRVINE, Calif. Immunis, Inc., a private biotech company developing a novel treatment for age and disease-related immune decline, announces that its Chairman, renowned neuroscientist Hans Keirstead,...
View ArticleClik here to view.
2seventy bio and JW Therapeutics Announce Strategic Partnership to Accelerate...
CAMBRIDGE, Mass. & SHANGHAI 2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, and JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology...
View ArticleClik here to view.
EdiGene to Present Preliminary Safety and Efficacy Results of an Investigator...
BEIJING & CAMBRIDGE, Mass. EdiGene, Inc., a global, clinical-stage company focused on translating gene-editing technologies into transformative genetic medicines for patients with significant...
View ArticleClik here to view.
European Commission (EC) Approves LIVTENCITYTM▼ (maribavir) for the Treatment...
OSAKA, Japan & CAMBRIDGE, Mass. Takeda (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) has granted Marketing Authorization for LIVTENCITYTM (maribavir) for the treatment of...
View ArticleClik here to view.
New Crown Bioscience Publication Details Application of In Vitro 3D Organoids...
SAN DIEGO Crown Bioscience, a JSR Life Sciences company and Contract Research Organization (CRO), has announced the publication of its review paper entitled: Translational and Clinical Relevance of...
View ArticleClik here to view.
冠科生物新发表的论文详细介绍了体外3D类器官与匹配的PDX在临床相关肿瘤药物开发中的应用
圣迭戈 (美国商业资讯)–JSR Life Sciences旗下的合同研究组织(CRO)冠科生物(Crown Bioscience)日前发布了题为“PDX源性类器官模型在肿瘤学药物发现和开发中的转化和临床意义”的综述文章。...
View Article